Clinical trials · Oregon
Transthyretin Amyloidosis clinical trials in Oregon
We’re tracking 6 recruiting transthyretin amyloidosis studies with a site in Oregon — including Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Oregon
- NCT06465810Recruiting
Observational study for ATTR amyloidosis patients
This study follows patients with ATTR amyloidosis over time to understand how the disease affects them. It does not test a new treatment—instead, it asks you to fill out questionnaires about your health and symptoms to help doctors learn more about the condition.
Portland, OregonAges 18–130 - NCT07052903RecruitingPhase 3
RNA therapy for ATTR amyloidosis with heart involvement
This trial tests an experimental RNA therapy (nucresiran) for people with transthyretin amyloidosis that causes heart problems (cardiomyopathy). It aims to lower the abnormal protein buildup to help heart function.
Portland, OregonAges 18–85 - NCT05758493RecruitingPhase 2
Iodine-124 scan study for systemic amyloidosis
This Phase 2 study tests an iodine-based scan medicine to help learn how systemic amyloidosis affects the body and organs. It may help doctors better characterize the disease using specific imaging tests.
Portland, OregonAges 40–90 - NCT06563895RecruitingPhase 3
Testing acoramidis to prevent ATTR amyloidosis in gene carriers
This trial tests a daily pill called acoramidis to see if it can prevent ATTR amyloidosis in people who carry a gene mutation but have no symptoms yet. It aims to stop the disease before it starts.
Portland, OregonAges 18–75 - NCT06128629RecruitingPhase 3
A study of NTLA-2001 for transthyretin amyloidosis with heart problems
This study tests a new treatment, NTLA-2001, for people with a type of heart disease called transthyretin amyloidosis with cardiomyopathy. It aims to see if the medicine can help improve heart function and quality of life.
Portland, OregonAges 18–90 - NCT07207811RecruitingPhase 3
Study of coramitug for heart failure from ATTR amyloidosis
This study tests an investigational medicine called coramitug in people with heart failure caused by ATTR amyloidosis, a condition where abnormal protein builds up in the heart. The goal is to see if it can slow or improve heart function.
Portland, OregonAges 18 years+
Transthyretin Amyloidosis trials by city in Oregon
Where these studies are running in Oregon
Institutions with a site for the recruiting transthyretin amyloidosis studies listed above.
- Oregon Health and Science University · 4 studies
- Clinical Trial Site
- Research Site
What taking part in a transthyretin amyloidosis study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Transthyretin Amyloidosis trials in other states
Common questions
- Are there transthyretin amyloidosis clinical trials in Oregon?
- Yes. We're currently tracking 6 recruiting transthyretin amyloidosis studies with a site in Oregon, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a transthyretin amyloidosis study in Oregon?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Oregon to take part?
- Not necessarily. These studies have a site in Oregon, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a transthyretin amyloidosis trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New transthyretin amyloidosis studies open in Oregon regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.